Monday to Friday, 8:00 AM to 8:00 PM ET
Resources for Patients and Healthcare Providers
Janssen CarePath can help make it simple for you to help your patients
Access support to help navigate payer processes
Janssen CarePath helps verify insurance coverage for your patients taking SPRAVATO™ and provides reimbursement information.
Affordability support to help your patients start and stay on the treatment you prescribe
Janssen CarePath can help you find out what affordability assistance may be available for your patients taking SPRAVATO™.
Janssen CarePath Savings Program
Eligible commercially insured patients pay $10 per treatment for SPRAVATO™ medication costs.*
Treatment support to help your patients get informed and stay on prescribed Janssen treatment
Janssen CarePath provides additional support to your patients, including patient education, web-based resources, and assistance finding a location that offers SPRAVATO™ treatment.
Dosing & Administration Resource
A helpful resource to learn how SPRAVATO™ is dosed and delivered.
Access & Reimbursement Guide
A guide designed to support the reimbursement process for SPRAVATO™.
Frequently asked questions
SPRAVATO™ (esketamine) is the s-enantiomer of racemic ketamine. There are no head-to-head studies comparing esketamine and ketamine infusion. SPRAVATO™ (esketamine) is delivered in a nasal spray form and ketamine is delivered intravenously.
There are no samples of SPRAVATO™ available—in accordance with federal guidelines, which prohibit the distribution of samples of class III medications.
SPRAVATO™ should be administered in conjunction with an oral antidepressant (AD). The new open-label oral AD initiated during Study 1 (short-term) was an SSRI in 32% of patients and an SNRI in 68% of patients.
The cost of SPRAVATO™ to your patients is dependent on their insurance plan. Janssen CarePath offers access and affordability options for your patients, depending on their plan.
If a patient misses treatment sessions, and depression symptoms worsen, consider returning your patient to their previous dosing schedule (ie, every 2 weeks to once weekly, once or twice per week), per clinical judgment.
No, under the REMS, SPRAVATO™ must be administered in a certified healthcare setting. Due to the possibility of delayed or prolonged sedation or dissociation in some cases, patients should be monitored by a healthcare professional for at least 2 hours following each treatment session, or until the clinician determines the patient is safe to leave.
Caution patients that SPRAVATO™ may impair their ability to drive or operate machinery. Instruct patients not to engage in potentially hazardous activities requiring complete mental alertness and motor coordination, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.
1.SPRAVATO™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. March 2019.